Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16822027 | 0.85 | AOC3 (0.38) | CYP17A1NOS3NOS1NOS2CYP11B1 | |
| SCHEMBL14290733 | 0.85 | ATM (0.33) | CYP17A1NOS3NOS1NOS2 | |
| SCHEMBL14291273 | 0.85 | CYP17A1 (0.31) | CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL11151411 | 0.79 | — | — | |
| SCHEMBL12514815 | 0.79 | — | — | |
| SCHEMBL27289769 | 0.78 | — | — | |
| SCHEMBL27272293 | 0.78 | — | — | |
| SCHEMBL9009276 | 0.77 | CYP11B2 (0.45) | CYP11B2 | |
| SCHEMBL25596754 | 0.77 | CYP11B2 (0.40) | CYP11B1CYP11B2 | |
| SCHEMBL1132721 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3468967-B1 | COMPOUNDS CONTAINING BENZO[D][1,3]OXATHIOLE, BENZO[D][1,3]OXATHIOLE 3-OXIDE OR BENZO[D][1,3]OXATHIOLE 3,3-DIOXIDE AND METHODS/USES THEREOF AS AGONISTS OF G PROTEIN-COUPLED RECEPTOR 119 | PRAMANA PHARMACEUTICALS INC (CA) | 2023-07-26 | — | — | EP | disclosed |
| EP-4006035-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Neupharma, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| US-11276825-B2 | Organic molecules for use in organic devices | CYNORA GMBH (DE) | 2022-03-15 | — | — | US | disclosed |
| US-20210184134-A1 | ORGANIC MOLECULES FOR USE IN ORGANIC DEVICES | SAMSUNG DISPLAY CO., LTD. (KR) | 2021-06-17 | — | — | US | disclosed |
| US-10947214-B2 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2021-03-16 | — | — | US | disclosed |
| US-10399957-B2 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2019-09-03 | — | — | US | disclosed |
| EP-3279193-B1 | COMPOUNDS COMPRISING A PHTHALIMIDE GROUP AND CARBAZOLE OR ITS ANALOGUES FOR USE IN ORGANIC OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2019-05-08 | — | — | EP | disclosed |
| US-20180037570-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2018-02-08 | — | — | US | disclosed |
| WO-2018024723-A1 | PHTHALIMIDE AND CARBAZOLE OR ANALOGS THEREOF CONTAINING COMPOUNDS FOR USE IN ORGANIC OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2018-02-08 | — | — | WO | disclosed |
| EP-3279193-A1 | COMPOUNDS COMPRISING PHTHALIMIDE AND CARBAZOLE OR ITS ANALOGUES FOR USE IN ORGANIC OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2018-02-07 | — | — | EP | disclosed |
| US-20100197716-A1 | N-LINKED HETEROCYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-05 | — | — | US | disclosed |
| US-20100152163-A1 | AZEPINO[4,5-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2010-06-17 | — | — | US | disclosed |
| US-7728008-B2 | N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-01 | — | — | US | disclosed |
| US-7700620-B2 | C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-20 | — | — | US | disclosed |
| US-20090281131-A1 | DIEBENZOFURAN DERIVATIVES AS INHIBITORS OF PDE-4 AND PDE-10 | MYLAN LABORATORIES LIMITED (IN) | 2009-11-12 | — | — | US | disclosed |
| US-20090239854-A1 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. | 2009-09-24 | — | — | US | disclosed |
| US-20090203665-A1 | HETEROCYCLIC-SUBSTITUTED PHENYL METHANONES | JOLIDON SYNESE | 2009-08-13 | — | — | US | disclosed |
| US-7557114-B2 | Heterocyclic-substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7550499-B2 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203665-A1 | HETEROCYCLIC-SUBSTITUTED PHENYL METHANONES | CYP2B6, CYP2D6, CYP1A2 | CYP17A1 59/4885NOS3 3017/4885NOS1 3389/4885 |
| US-20210184134-A1 | ORGANIC MOLECULES FOR USE IN ORGANIC DEVICES | CHRM1, C1S, DNMT3L | CYP17A1 1820/4885NOS3 95/4885NOS1 389/4885 |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | ABL1, MAP3K20, MAP3K1 | CYP17A1 1984/4885NOS3 2135/4885NOS1 2266/4885 |
| US-20180037570-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | CYP17A1 2655/4885NOS3 3775/4885NOS1 3551/4885 |
| US-20100197716-A1 | N-LINKED HETEROCYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | P2RY1, P2RY11, P2RY13 | CYP17A1 4593/4885NOS3 3310/4885NOS1 2349/4885 |
| US-20100152163-A1 | AZEPINO[4,5-B]INDOLES AND METHODS OF USE | HTR2C, HTR5A, HTR4 | CYP17A1 2740/4885NOS3 2857/4885NOS1 3510/4885 |
| US-10947214-B2 | TLR7/8 antagonists and uses thereof | TLR7, TLR8, TLR9 | CYP17A1 2655/4885NOS3 3775/4885NOS1 3551/4885 |
| US-10399957-B2 | TLR7/8 antagonists and uses thereof | TLR7, TLR8, TLR9 | CYP17A1 2655/4885NOS3 3775/4885NOS1 3551/4885 |
| US-11276825-B2 | Organic molecules for use in organic devices | AOX1, OR10J3, L1CAM | CYP17A1 940/4885NOS3 40/4885NOS1 20/4885 |
| US-20090281131-A1 | DIEBENZOFURAN DERIVATIVES AS INHIBITORS OF PDE-4 AND PDE-10 | PDE4A, PDE4B, PDE12 | CYP17A1 521/4885NOS3 93/4885NOS1 79/4885 |
| US-20090239854-A1 | Tetracyclic compounds | HTR2C, HTR3D, HTR5A | CYP17A1 4401/4885NOS3 4454/4885NOS1 4511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.